News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New € 239K Project Award For MEDIAN Technologies



12/5/2013 11:22:11 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Sophia Antipolis, France – December 5, 2013 – MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced that it has been selected to provide imaging services in a new phase II clinical trial for gastric cancer sponsored by an Asian leading biotechnology company.

Within the framework of the project, imaging data will be acquired from 38 clinical sites based in four Asian countries. Anticipated total enrollment is 220 patients with a forecasted start date mid-2015. For the purposes of the study, MEDIAN will provide services for imaging data collection and quality control.

The anticipated amount for the project, awarded through MEDIAN’s alliance with its strategic CRO partner, is € 239,000 (eq. $ 310,000).

“MEDIAN has already won several Asia-based clinical trial imaging projects led by major pharmaceutical companies; however, this is our first study award with an Asian biotechnology company. It illustrates our commitment to deliver our imaging services in this region, today the world’s fastest growing region regarding oncology clinical trials”, said Nicolas Dano, Director of Business Development, Europe and Asia.

Since the beginning of 2013, MEDIAN Technologies has recorded €4.5M of orders, including €1,0M of firm orders and €3.5M of project awards [*].

[*] A project award notifies a company that their solution has been selected for a given project. A binding contract is then signed within the 18 months following the award, upon confirmation of the upstream clinical results.

About MEDIAN Technologies: MEDIAN Technologies provides advanced imaging solutions for diagnosing and monitoring cancer patients in clinical trials and in routine clinical practice. MEDIAN collaborates with institutes at the cutting edge of medical imaging, including the French National Institute for Computer Science and Control (INRIA), the University of Chicago, and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL). MEDIAN is present in the market through direct and indirect sales of its LMS solutions and through alliances with specialist cancer centers in Europe and the USA. MEDIAN has a strategic partnership with Canon for the development of new technologies, and a strategic partnership with the world’s largest CRO to offer integrated imaging services for clinical trials to customers worldwide.

Based in Sophia Antipolis, France, MEDIAN was founded in 2002 by Fredrik Brag (CEO), Gérard Milhiet, and Arnaud Butzbach. The company has a staff of 45, over half of whom work in R&D, and has a US-based subsidiary in the Boston area.

MEDIAN has received the label "Innovative company" by OSEO and is listed on NYSE Euronext Paris' Alternext market (ISIN: FR0011049824, ticker: ALMDT).

For more information on MEDIAN, please visit: www.mediantechnologies.com

CONTACTS

MEDIAN Technologies Fredrik Brag, CEO +33 4 92 90 65 82 fredrik.brag@mediantechnologies.com

Press

ALIZE RP Caroline Carmagnol + 33 6 64 18 99 59 caroline@alizerp.com

Christian Berg

+ 33 1 70 22 53 86 christian@alizerp.com

Investors

ACTIFIN Anaïs de Scitivaux + 33 1 56 88 11 14 adescitivaux@actifin.fr

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES